Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel vs CMF in Adjuvant Breast Cancer
NCT00193011Phase 3Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2002
- Primary completion
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Disease-Free Survival at 18 months. Started Mar 2002; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193011.